Edition:
India

Dynavax Technologies Corp (DVAX.OQ)

DVAX.OQ on NASDAQ Stock Exchange Capital Market

12.00USD
21 Sep 2018
Change (% chg)

$-0.20 (-1.64%)
Prev Close
$12.20
Open
$12.15
Day's High
$12.30
Day's Low
$11.85
Volume
1,534,522
Avg. Vol
256,920
52-wk High
$24.45
52-wk Low
$11.40

Latest Key Developments (Source: Significant Developments)

Dynavax Technologies Q2 Loss Per Share $0.63
Tuesday, 7 Aug 2018 

Aug 6 (Reuters) - Dynavax Technologies Corp ::DYNAVAX REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.63.Q2 EARNINGS PER SHARE VIEW $-0.63 -- THOMSON REUTERS I/B/E/S.Q2 SALES $1.3 MILLION VERSUS I/B/E/S VIEW $1.6 MILLION.  Full Article

Dynavax says FDA approves Heplisav-B for Hepatitis B prevention in adults
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Dynavax Technologies Corp :Dynavax announces FDA approval of Heplisav-B for prevention of Hepatitis B in adults.Dynavax Technologies Corp - ‍expects to commercially launch Heplisav-B in United States in Q1 of 2018​.  Full Article

Dynavax reports Q3 loss per share $0.38
Friday, 3 Nov 2017 

Nov 3 (Reuters) - Dynavax Technologies Corp :Dynavax reports third quarter 2017 financial results.Q3 loss per share $0.38.Q3 earnings per share view $-0.47 -- Thomson Reuters I/B/E/S.Dynavax Technologies Corp - Qtrly total revenue $53,000 versus $162,000‍​.Dynavax Technologies - ‍Cash, cash equivalents & marketable securities were $191.7 million at Sept 30, 2017 compared to $81.4 million at Dec 31, 2016​.  Full Article

Dynavax initiates clinical trial in non-small cell lung cancer with a novel inhaled TLR9 Agonist
Thursday, 19 Oct 2017 

Oct 19 (Reuters) - Dynavax Technologies Corp :Dynavax initiates clinical trial in non-small cell lung cancer with a novel inhaled TLR9 Agonist in combination with Anti-PD-1 therapy.Dynavax Technologies - ‍dose escalation study is expected to enroll about 24 patients in 5 cohorts with advanced NSCLC.  Full Article

Dynavax Technologies received anticipated requests for information from FDA review team in connection with pending BLA for HEPLISAV-B
Monday, 3 Oct 2016 

Dynavax Technologies Corp : Review team's questions are in line with company's expectations . Working with FDA to resolve remaining questions in order to enable FDA to complete review by scheduled PDUFA action date of Dec 15 . Received anticipated requests for information from FDA review team in connection with pending BLA for HEPLISAV-B .PDUFA action date of December 15, 2016 remains unchanged.  Full Article

BRIEF-Dynavax Reports Q1 Loss Per Share Of $0.63

* Q1 EARNINGS PER SHARE VIEW $-0.49 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage: